EVALUATION OF CELLULAR IMMUNE RESPONSE DURING XENOVACCINE THERAPY OF THE PATIENTS WITH STAGE IV OF COLORECTAL CANCER
https://doi.org/10.15789/1563-0625-2006-1-67-72
Abstract
Abstract. Thirty-seven patients with stage colorectal cancer stage IV were subjected to immunotherapy using a polyantigenic vaccine, prepared, basically, from lyzed cells of murine melanoma (B16) and murine carcinoma (LLC) cells. The inducing course of xenovaccine therapy consisted of 10 subcutaneous immunizations (5 injections weekly followed by 5 bi-weekly). Consolidating treatment included monthly vaccinations. Ther xenovaccine therapy was not associated with any serious adverse effects, and did not influence the composition of blood lymphocyte subsets. Significant increase in cellular immune reactions to vaccinal carcinoma-associated antigens occurred in the patients after an inducing treatment, as determined by both skin and antigen-driven blastogenesis test. The overall 2-year survival of thirty-seven stage IV colorectal cancer patients was shown to be significantly better, than in control group (37 clinically comparable patients), with median survival rates of 17 and 7 months, respectively.
About the Authors
M. A. FeldeRussian Federation
D. M. Samarin
Russian Federation
N. A. Niza
Russian Federation
A. A. Shishkov
Russian Federation
O. V. Poveshenko
Russian Federation
E. A. Kashchenko
Russian Federation
V. I. Seledtsov
Russian Federation
G. V. Seledtsova
Russian Federation
V. A. Kozlov
Russian Federation
References
1. Тимофеев Ю.М. Колоректальный рак: современные аспекты диагностики и лечения // Русский медицинский журнал. –2004. -№ 11. –С.1-8.
2. Bergman P.J., McKnight J., Novosad A., Charney S., Farrelly J., Craft D., Wulderk M., Jeffers Y., Sadelain M., Hohenhaus A.E., Segal N., Gregor P., Engelhorn M., Riviere I., Houghton A.N., Wolchok J.D. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial // Clin.Cancer Res.-2003. -V.9. -P.1284-1290.
3. Berzofsky J.A., Terabe M., Oh S.K., Belyakov I.M., Ahlers J.D., Janik J.E., Morris J.C. Progress on new vaccine strategies for the immunotherapy and prevention of cancer // The Journal of Clinical Investigation. -2004. –Vol.113. –P.1515-1525.
4. Galili U., LaTempe D.C. Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity // Immunology Today. –1997. – Vol.18. –P.281-285.
5. Graf N., Adam C., Mocikat R. Persistence of xenogenized vaccine cells in vivo // Int.J.Cancer. –2003. –V.105. –P.217-220.
6. Luo F., Wei Y., Kan B. Anti-tumor immune response agains mouse melanoma to xenogeneic vaccination // Zhonghua Zhong Liu Za Zhi. -2001. -Vol.23. - P.118-121.
7. Naftzger C., Takechi Y., Kohda H., Hara I., Vijayasaradhi S., Houghton A.N. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity // PNAS. –1996. –Vol.93. –P.14809-14814.
8. Rafiq K., Bergtold A., Clynes R. Immune complex-mediated antigen presentation induces tumor immunity // J Clin Invest. -2002. -Vol1. – P.71-79.
9. Renkvist N., Castelli C., Robbins P.F., Parmiani G. A listing of human tumor antigens recognized by T cells // Cancer Immunology Immunotherapy. –2001. –Vol.50. –P.3-15.
10. Srinivasan R., Wolchok J.D. Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines // Journal of translational medicine. -2004. –V.2. –P.1.
11. Van Den Eynde B.J., Gaugler B., Brandle D., Gulloux Y., Van Der Bruggen P., Coulle P., Brichard V., Boon T. Characterization of antigens recognized by T cells on human tumors // Symposium in Immunology YI, Springer-Verlag, Heidelberg. -1997. -P.1-11.
12. Yoshihito K., Koichi S., and James J.M. Comparative analysis of necrotic and apoptotic tumor cells as a sourse of antigen(s) in dendritic cell-based immunisation // Cancer Research. –2001. -Vol.61. -P.8105-8109.
Review
For citations:
Felde M.A., Samarin D.M., Niza N.A., Shishkov A.A., Poveshenko O.V., Kashchenko E.A., Seledtsov V.I., Seledtsova G.V., Kozlov V.A. EVALUATION OF CELLULAR IMMUNE RESPONSE DURING XENOVACCINE THERAPY OF THE PATIENTS WITH STAGE IV OF COLORECTAL CANCER. Medical Immunology (Russia). 2006;8(1):67-72. (In Russ.) https://doi.org/10.15789/1563-0625-2006-1-67-72